{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:50:07Z","timestamp":1790686207775,"version":"4.1.0"},"reference-count":17,"publisher":"American Society of Hematology","issue":"14","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2015,10,1]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>Ibrutinib induces a rapid, dramatic, and sustained response in MCL patient with symptomatic CNS relapse. Ibrutinib penetration through the blood-brain barrier was confirmed using plasma and cerebrospinal fluid pharmacokinetic analyses.<\/jats:p>","DOI":"10.1182\/blood-2015-05-647834","type":"journal-article","created":{"date-parts":[[2015,8,4]],"date-time":"2015-08-04T01:49:37Z","timestamp":1438652977000},"page":"1695-1698","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":133,"title":["Activity of ibrutinib in mantle cell lymphoma patients with central nervous system relapse"],"prefix":"10.1182","volume":"126","author":[{"given":"Sophie","family":"Bernard","sequence":"first","affiliation":[{"name":"Hemato-oncology Department, Assistance Publique-H\u00f4pitaux de Paris (APHP), H\u00f4pital Saint-Louis, Paris, France;"},{"name":"Paris Diderot Universit\u00e9, Sorbonne Paris Cit\u00e9, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauriane","family":"Goldwirt","sequence":"additional","affiliation":[{"name":"Pharmacology Department, APHP, H\u00f4pital Saint-Louis, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandy","family":"Amorim","sequence":"additional","affiliation":[{"name":"Hemato-oncology Department, Assistance Publique-H\u00f4pitaux de Paris (APHP), H\u00f4pital Saint-Louis, Paris, France;"},{"name":"Paris Diderot Universit\u00e9, Sorbonne Paris Cit\u00e9, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Brice","sequence":"additional","affiliation":[{"name":"Hemato-oncology Department, Assistance Publique-H\u00f4pitaux de Paris (APHP), H\u00f4pital Saint-Louis, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josette","family":"Bri\u00e8re","sequence":"additional","affiliation":[{"name":"Pathology Department, APHP, H\u00f4pital Saint-Louis, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"de Kerviler","sequence":"additional","affiliation":[{"name":"Radiology Department, APHP, H\u00f4pital Saint-Louis, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samia","family":"Mourah","sequence":"additional","affiliation":[{"name":"Paris Diderot Universit\u00e9, Sorbonne Paris Cit\u00e9, Paris, France;"},{"name":"INSERM UMR-S 976, H\u00f4pital Saint-Louis, Paris, France; and"},{"name":"Pharmacology-Genetics Laboratory, APHP, H\u00f4pital Saint-Louis, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Sauvageon","sequence":"additional","affiliation":[{"name":"Pharmacology Department, APHP, H\u00f4pital Saint-Louis, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Thieblemont","sequence":"additional","affiliation":[{"name":"Hemato-oncology Department, Assistance Publique-H\u00f4pitaux de Paris (APHP), H\u00f4pital Saint-Louis, Paris, France;"},{"name":"Paris Diderot Universit\u00e9, Sorbonne Paris Cit\u00e9, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111901504842800_B1","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"Swerdlow","year":"2008","edition":"4th ed"},{"issue":"8","key":"2019111901504842800_B2","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1093\/annonc\/mdt139","article-title":"Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network.","volume":"24","author":"Cheah","year":"2013","journal-title":"Ann Oncol"},{"issue":"29","key":"2019111901504842800_B3","doi-asserted-by":"crossref","first-page":"13075","DOI":"10.1073\/pnas.1004594107","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy.","volume":"107","author":"Honigberg","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"2019111901504842800_B4","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"key":"2019111901504842800_B5","article-title":"Long-term follow-up of MCL patients treated with single-agent ibrutinib: Updated safety and efficacy results.","author":"Wang","year":"2015","journal-title":"Blood"},{"issue":"12","key":"2019111901504842800_B6","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1023\/A:1007669411738","article-title":"Bioanalytical method validation--a revisit with a decade of progress.","volume":"17","author":"Shah","year":"2000","journal-title":"Pharm Res"},{"key":"2019111901504842800_B7","author":"FDA"},{"issue":"27","key":"2019111901504842800_B8","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111901504842800_B9","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","article-title":"Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies.","volume":"31","author":"Advani","year":"2013","journal-title":"J Clin Oncol"},{"key":"2019111901504842800_B10","article-title":"CSF distribution and therapeutic drug monitoring of ibrutinib in patients with CNS dissemination in mantle cell lymphoma (MCL).","author":"Goldwirt"},{"issue":"1","key":"2019111901504842800_B11","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1182\/blood-2014-05-521898","article-title":"Mantle cell lymphoma: evolving management strategies.","volume":"125","author":"Campo","year":"2015","journal-title":"Blood"},{"issue":"4","key":"2019111901504842800_B12","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrc3702","article-title":"Targeting Bruton\u2019s tyrosine kinase in B cell malignancies.","volume":"14","author":"Hendriks","year":"2014","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"2019111901504842800_B13","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.","volume":"369","author":"Byrd","year":"2013","journal-title":"N Engl J Med"},{"issue":"15","key":"2019111901504842800_B14","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","article-title":"Ibrutinib in previously treated Waldenstr\u00f6m\u2019s macroglobulinemia.","volume":"372","author":"Treon","year":"2015","journal-title":"N Engl J Med"},{"issue":"9","key":"2019111901504842800_B15","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/S1470-2045(14)70311-0","article-title":"Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.","volume":"15","author":"Younes","year":"2014","journal-title":"Lancet Oncol"},{"issue":"2","key":"2019111901504842800_B16","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1007\/s12032-013-0520-0","article-title":"Central nervous system prophylaxis in patients with aggressive diffuse large B cell lymphoma: an analysis of 3,258 patients in a single center.","volume":"30","author":"Avil\u00e9s","year":"2013","journal-title":"Med Oncol"},{"key":"2019111901504842800_B17","author":"FDA"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/126\/14\/1695\/1388821\/1695.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/126\/14\/1695\/1388821\/1695.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T06:50:55Z","timestamp":1574146255000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/126\/14\/1695\/34421\/Activity-of-ibrutinib-in-mantle-cell-lymphoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,1]]},"references-count":17,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2015,10,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2015-05-647834","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,1]]}}}